Sensus Healthcare, Inc.
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the…
1D
+0.0%
1W
-6.1%
1M
-9.8%
6M
-38.3%
YTD
-30.4%
1Y
-16.3%
2Y
-59.4%
5Y
-30.6%
10Y
-54.4%
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~180% stronger price swings than usual
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.75
MEDIAN
US$4.75
PRICE TARGET HIGH
US$5.50
0
STRONG BUY
6
BUY
3
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 14/08/2026
P/E
-2.95
P/B
1.24
EV/EBITDA
-3.32
RETURN ON EQUITY
-23.7%
NET MARGIN
-382.1%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
81.3%
FLOAT SHARES
13,389,317
AVG. DAILY VOLUME (30D)
21,361
Sachetta Eric
Sachetta Eric
Sachetta Eric
Sachetta Eric
Sachetta Eric
Sensus Healthcare, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Joseph C. Sardano, the company employs around 60 people.
The IPO was on 26/07/2016; the stock trades on NASDAQ under the ticker SRTS.
9 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$4.75, ranging from US$4.00 to US$5.50, with a median of US$4.75.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 180% stronger than usual.
No, Sensus Healthcare currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
Clicking "Analyze stock" lets five strategies assess Sensus Healthcare against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.